91097-81-3

Upstream product

• 53360-89-7 2-amino-1-(3-chloro-phenyl)-ethanol 
• 78069-08-6 1-(4-carbomethoxymethoxyphenyl)-propan-2-one 

Relevant academic research and scientific papers

TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION WITH BETA3-ADRENERGIC AGONISTS

This invention relates to a method of treating glaucoma or reducing intraocular pressure in a patient in need of such treatment which is based on the topical administration to the eye of a mammal or the systemic administration of a compound of the formula: STR1 wherein E', W', and the R groups are defined in the disclosure.

Medical use for atypical beta-adrenoceptor agonists

The present invention relates to the use of compounds which act as agonists at atypical beta-adrenoceptors, for the treatment of gastrointestinal disorders, especially peptic ulceration, oesophagitis, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and gastrointestinal ulcerations, especially when induced by non-steroidal anti-inflammatory drugs or corticosteroids.

Method for administering ethanolamine derivatives to livestock

A method for increasing the weight gain and/or improving the feed utilization efficiency of livestock is described which comprises the oral or non-oral administration to livestock of an effective, non-toxic amount of a compound of formula (XX): STR1 or a salt thereof, in which W is phenyl optionally substituted by halogen or trifluoromethyl, or a benzofuran-2-yl group, R1x is hydrogen or methyl, R2x is carboxyl or a group O--Z4 --CO2 H or an ester or amide thereof; a group O--E1 --NR3x R4x or a group O--E1 --OR5x, wherein R3x, R4x and R5x each represents hydrogen or C1-6 alkyl, Z4 is a C1-6 straight or branched alkylene chain, x is 1 or 2, y is 2 or 3, and E1 is C2-7 straight or branched alkylene chain with at least two carbon atoms separating the two heteroatoms in the group R2x. Also described is a veterinarily acceptable premix formulation administrable in a veterinarily effective amount in feed or water comprising a compound of the formula (XX) or, where appropriate, a veterinarily acceptable salt, ester or amide thereof; in association with a veterinarily acceptable carrier therefor. Additionally, a veterinarily acceptable premix formulation comprising from about 0.001% to about 95% by weight of a compound of formula (XX) administrable in feed or water or, where appropriate, a veterinarily acceptable salt, ester or amide thereof, together with a veterinarily acceptable carrier.

Ethanamine derivatives their preparation and use in pharmaceutical compositions

The compounds of formula (II): STR1 in which R1 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R2 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group; R3 is a hydrogen, chlorine or bromine atom or a hydroxyl group, R4 is a hydrogen atom or a methyl group; R5 is a hydrogen atom or a methyl group; R6 is a hydrogen, fluorine or chlorine atom or a methyl, methoxyl or hydroxy group; X is an oxygen atom or a bond; Y is an alkylene group of up to 6 carbon atoms or a bond; and Z is an alkylene, alkenylene or alkynylene group of up to 10 carbon atoms, have been found to possess anti-obesity and/or anti-hyperglycaemic activity.